Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that, in female patients with idiopathic telogen effluvium, a supplement containing zinc, biotin, and other nutrients significantly improved hair loss and quality over 180 days, whereas another supplement with different ingredients had less consistent effects.

This study found that cyproterone acetate with ethynyl estradiol improved acne and seborrhea within 3–6 months in women, but had less satisfactory results for alopecia and hirsutism.

The combination of tretinoin, minoxidil, and betamethasone valerate may cause severe scalp inflammation.

This study reported that an ATRA-loaded nanostructured lipid carrier gel (ATRA-NLC-Gel) improved symptoms of alopecia areata in mice by enhancing transdermal drug delivery, reducing skin irritation, and promoting hair regrowth through targeted follicle enrichment and pathway activation.

This article discusses using topical tretinoin with intralesional triamcinolone acetonide for alopecia areata in northern Saudi Arabia, but it reports no new clinical findings.

This report describes a child with ulerythema ophryogenes marked by eyebrow hair absence and progressive skin atrophy, whose condition did not improve despite elevated vitamin A levels via injections.

This case report documents the development of vitiligo-like lesions in a patient with autoimmune thyroiditis following the use of topical squaric acid dibutylester for alopecia.

This case report details a 5-month-old infant with acrodermatitis enteropathica, linked to zinc deficiency from total parenteral nutrition, who showed improvement using zinc spray and cream, contrasting with typical literature outcomes.

This preclinical study observed that a nanoencapsulated ingredient complex, AcPi, may prevent hair follicle aging and hair loss by reducing oxidative stress, enhancing mitochondrial activity and WNT/β-catenin signaling, and controlling androgenic metabolism when tested on human scalp cultures.

This study presents case reports of four patients with alopecia areata or alopecia universalis, highlighting varied responses to treatments like prednisone, intralesional triamcinolone, and squaric acid dibutyl ester.

This research found that Nano-Transfersomes containing Vitamin E and aloe vera showed improved permeability and prolonged drug release compared to a marketed formulation, with no skin irritancy observed in mice, potentially offering a sustainable and biocompatible option for psoriasis management.

In this study, 40% of alopecia areata patients using topical 2% tofacitinib ointment achieved greater than 50% improvement in hair regrowth after six months, showing significant efficacy compared to controls, with no serious adverse effects reported.

This paper reviews the challenges of treating alopecia areata affecting eyelashes and discusses the risks associated with traditional therapies; it reports no new clinical results.

In this study, TyroSpheres were used to encapsulate adapalene, increasing its solubility and enhancing skin distribution while reducing irritancy compared to a commercial formulation, indicating promise for acne treatment in ex vivo and in vitro settings.

This study found that oral tofacitinib significantly reduced alopecia severity and improved quality of life over 12 months for children with moderate to severe alopecia areata, though the authors recommend more research due to the small sample size and absence of a control group.

This study found that MPEG-dihexPLA micelles significantly improved the skin deposition of tacrolimus compared to a marketed ointment, suggesting better targeted delivery with reduced systemic absorption.

This case study highlights a pediatric instance of eruptive vellus hair cysts partially responding to calcipotriene cream, aiming to remind clinicians about this often overlooked condition.

This study compared oral tofacitinib and methotrexate in treating moderate-to-severe alopecia areata, finding that tofacitinib was more effective at reducing SALT scores and improving scalp hair assessment PRO scores, though both treatments reduced psychological distress similarly without serious adverse effects.

In this study, researchers developed topical tofacitinib-loaded cationic lipid nanoparticles, which improved absorption and targeted hair follicles in an ex vivo pig ear model, showing promise in treating alopecia areata by reducing symptoms through the JAK/STAT pathway.

This report details the development of a PSR™ Terminalia extract with antioxidant and anti-aging potential, highlighting its rich composition in phenolic acids, polysaccharides, and organic acids, without new clinical results.

In this case study, oral folic acid therapy resulted in noticeable improvement and eventual recovery from hair loss and skin issues in a three-week-old Charolais calf.

In this case report, an 11-year-old girl with acrodermatitis enteropathica experienced a complete resolution of symptoms following oral zinc therapy, highlighting its effectiveness in managing this condition.

This study found that both topical tretinoin and oral isotretinoin altered the free fatty acid profile of sebum in acne patients, affecting bacterial growth differently for S. epidermidis and S. aureus.

This study found that liposomes coated with cationic polymers, chitosan and Eudragit EPO, showed improved physicochemical stability and enhanced skin diffusion of aciclovir and minoxidil compared to uncoated liposomes.

This study found that combining oral isotretinoin with topical treatments was more effective than topical treatments alone for improving frontal fibrosing alopecia symptoms, despite some side effects.

In this randomized control trial, the researchers found that intralesional triamcinolone acetonide led to higher hair density increases than Vitamin D supplementation in alopecia areata patients, although potential hair regrowth was also noted with Vitamin D in those with deficient levels.

This study observed that early treatment with ritlecitinib in patients with alopecia areata, especially when severity is low, led to more favorable responses, and continued improvement was seen up to 24 months, offering guidance on treatment timing and duration.

In this study, 80% of pediatric patients with alopecia areata treated with calcipotriol/betamethasone ointment showed hair regrowth over 12 weeks, suggesting it may be an effective option, though 20% had no improvement or worsening symptoms.